

Efficacy of combination therapy (Sofosbuvir, Pegylated interferon and Ribavirin) in treatment of chronic hepatitis C in Egyptian patients

Thesis

Submitted for partial fulfillment of master degree in
Internal medicine

By

Dr. Mohsen Ebrahim Abdelhamid Ali Eldragini
M.B.B.Ch,

Supervised By

Prof.Dr.Samir Abd el Hamid Ghait

Professor of internal medicine,
Gastroenterology and hepatology
Faculty of medicine Ain Shams university

Ass.Prof.Dr Inas Elkhedr Mohamed

Assistant Professor of internal medicine,
Gastroenterology and hepatology
Faculty of medicine Ain Shams university

Dr. Hany Haroun Kaysar

Lecturer of internal medicine,
Gastroenterology and hepatology
Faculty of medicine Ain Shams university.

Faculty of Medicine
Ain Shams University
2016

Extreme remedies are very appropriate for extreme diseases.

Hippocrates, Aphorisms, 6



Acknowledgement

First and foremost thanks to ALLAH, the most merciful.

I wish to express my deepest appreciation and sincere gratitude to **Prof.Dr.Samir Abd el Hamid Ghait** Prof. of internal medicine, Faculty of Medicine, Ain Shams University, for his continuous encouragement, kind supervision, valuable instructions and sincere advice which have been the main factors to complete this work. It was a great honor for me to work under his supervision.

Words can never express my deepest gratitude, appreciation and greatest respect to **Prof.Dr Inas Elkhedr Mohamed Ass. Prof** of internal medicine , Faculty of Medicine, Ain Shams University, for her close supervision, continuous guidance, great help and indispensable advice in every step of this work. She has generously devoted much of her valuable time, experience and effort for planning and supervision of this work and for presenting it in an ideal form.

I am also delighted to express my supreme gratitude and everlasting appreciation to **Ass Dr. Hany Haroun Kaysar Lecturer of internal medicine** Faculty of Medicine, Ain Shams University, for his keen supervision, great support, endless help and continuous guidance during all stages of this work.

I am also delighted to express my deep gratitude and thanks to all my dear professors and my colleagues in Ain Shams University and in national hepatology and tropical medicine research institute for their help and support and to all patients included in this work and every one made any effort for this work to be a reality.

A special dedication to my family for their never ending care. They were always supporting me and encouraging me to continue and finish this work.

List of Contents

Subject	Page no.
List of Abbreviations	i
List of Tables	iv
List of Figures	vi
Introduction	2
Aim of work	7
Review of Literature	
➤ Chapter 1: Hepatitis C virus	9
➤ Chapter 2: Hepatitis C	27
➤ Chapter 3: Management of HCV	57
Patients and Methods	86
Results	91
Discussion	101
Summary	113
Conclusion	115
Recommendations	117
References	119
Arabic summary	--

List of Abbreviations

AAR	ALT/AST ratio
AASLD	American Association for the Study of Liver Diseases
AFP	α -Foetoprotein
AIH	Autoimmune hepatitis
ALT	Alanine Aminotransferase
ANA	Antinuclear antibody
API	age/platelet index
APRI	AST to Platelet Ratio Index
AST	Aspartate Aminotransferase
BMI	Body Mass Index
CBC	Complete Blood Count
CHB	chronic hepatitis B
CHC	Chronic Hepatitis C
CLD	chronic liver disease
DAA	Direct acting antiviral
EASL	European Association of Study of Liver
ECM	Extracellular Matrix
EIF-2	Eukaryotic Initiation Factor 2
FRT	Fibrosis routine test
GUCI	Göteborg University Cirrhosis Index
HA	Hyaluronic acid
HbcAg	Hepatitis B core Antigen
HBeAg	Hepatitis B e Antigen
HBIG	hepatitis B immune globulin
HBsAg	Hepatitis B surface antigen
HBV	Hepatitis B virus
HCC	Hepato cellular carcinoma
HCV	Hepatitis C virus
HDL	High Density Lipoprotein
HIV	Human immunodeficiency virus
IFN	interferon

IgG	Immunoglobulin G
IgM	immunoglobulin M
ISGs	IFN-stimulated genes
INR	International normalized ratio
IQR	Interquartile range
IRES	<u>Internal ribosome entry site</u>
Kb	Kilo-base pair
kPa	kilopascals
MAVS	mitochondrial antiviral signalling protein
MMP	matrix metalloproteinases
NHTMRI	National hepatology and tropical medicine research institute
NK cells	natural killer cells
LDL	low-density lipoproteins
LDLR	low-density lipoproteins receptor
MR elastography	Magnetic resonance elastography
NAFLD	Nonalcoholic fatty liver disease
NASH	Non alcoholic steatohepatitis
NHANES	National Health and Nutrition Examination Survey
NS	nonstructural proteins
NTR	nontranslated regions
ORFs	open reading frames
PBC	primary biliary cirrhosis
PCR	Polymerase Chain Reaction
PDGF	Platelet deriving growth factor
PICP	Procollagen type I carboxy-terminal peptide
PIIINP	Procollagen type III amino-terminal peptide
PIIINP or P3NP	Procollagen type III amino-terminal peptide
pDCs	plasmacytoid dendritic cells
PT	Prothrombin Time
RBV	Ribavirin
rER	rough endoplasmic reticulum
RIG-I	retinoic acid–inducible gene I

RNA	Ribonucleic acid
SNP	single nucleotide polymorphisms
TGF 1	transforming growth factor 1
TGFα	Transforming growth factor alpha
TGFβ	Transforming growth factor beta
The ELF group	The European Liver Fibrosis Group assay group
TIMP-1	Metalloproteinase 1
TIMPs	tissue inhibitors of metalloproteinases
TLR3	Toll-like receptor 3
TLR9	Toll-like receptor 9
UTR	<i>untranslated region</i>
VCTE	Vibration-Controlled Transient Elastography
VEGF	Vascular Endothelial Growth Factor
VLDL	very low-density lipoproteins

List of tables

(I) Tables in the review

Subject	Page no.
Table (1): <i>Size and main function of HCV proteins</i>	14-15
Table (2): Interpretation of HCV Assays	44
Table (3): Examples of Indirect serum markers	45-46
Table (4): Different sofosbuvir studies	72-73
Table (5): Treatment recommendations for HCV-monoinfected or HCV/HIV coinfectd patients with chronic hepatitis C without cirrhosis, including treatment - naïve patients and patients who failed on a treatment based on PegIFN-a and ribavirin (RBV).	83
Table (6): Treatment recommendations for HCV-monoinfected or HCV/HIV coinfectd patients with chronic hepatitis C with compensated (Child-Pugh A) cirrhosis, including treatment-naïve patients and patients who failed on a treatment based on PegIFN-a and ribavirin (RBV).	84

(2) Tables in the results

Subject	Page no.
Table (1): Demographic features of the studied patients	91
Table (2): Smoking and diabetes mellitus as risk factors	92
Table (3): interferon status, grade of fibrosis and PCR before treatment	92
Table (4): The grade of fibrosis In relation to other parameters	93
Table (5): The PCR after 4 week of treatment	94
Table (6): The SVR in relation to age and sex	95
Table (7) The SVR in relation to history of diabetes mellitus and smoking	96
<i>Table (8): The SVR in relation to PCR after 4 week of treatment</i>	97
Table (9): The SVR in relation to viral load before treatment	97
Table (10): The SVR in relation to interferon therapy.	98
Table (11): The SVR in relation to grade of fibrosis.	98

List of figures

(I) Figures in the review:

Subject	Page no.
Figure (1): Structure of Hepatitis C Virus	9
Figure (2): Schematic representation of the HCV genome and polyprotein processing.	11
Figure (3): Replication of Hepatitis C Virus	12
Figure (4): <i>Genomic organization of hepatitis C virus polyprotein</i>	14
Figure (5): Pathways of the interferon-mediated antiviral response.	22
Figure (6): Hepatitis C disease progression	28
Figure (7): Morphology of hepatic stellate cells in normal liver	33
Figure (8): Malignant transformation nodule	36
Figure (9): simple diagrammatic representation of various of action of DDAs	70

(2) Figures in the results:

Subject	Page no.
Figure (1): Pie charts of the age group and sex distribution.	91
Figure (2): Distribution of Grade of fibrosis	94
Fig (3): SVR in relation to the sex and age group.	95
<i>Fig (4): SVR in relation to the history of diabetes mellitus and smoking</i>	96
<i>Fig (5) SVR in relation to viral load</i>	97
<i>Fig (6) SVR in relation to previous Interferon therapy</i>	98
<i>Fig (7) SVR in relation grade of fibrosis</i>	99
Figure (8): Overall SVR	99